Selskabets formål er at drive handel og fabrikation samt dertil knyttet virksomhed
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 1 mia. | 46.1 mio. | 642.6 mio. | 291.7 mio. | 48 | |
CVR: 13902992
Secondary names: DERMALOG ApS, PHARMACODANE ApS
Compared to 408 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
STADA NORDIC ApS demonstrates a strong financial health with a significant upward trajectory in revenue and profit over the past few years. In 2024, the company reported revenue of 1.03 billion DKK and a profit of 46.1 million DKK, marking a substantial increase from 808.7 million DKK in revenue and 66.4 million DKK in profit in 2023. The equity position has also improved, rising to 291.7 million DKK, which indicates a solid foundation for future growth. However, profit margins have slightly decreased, suggesting potential concerns regarding cost management. Overall, STADA NORDIC ApS is well-positioned within the pharmaceutical wholesale industry, reflecting robust growth and stability.
AI-generated summary
Companies in the same industry and area
companydata.dk